Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 5 | 2022 | 207 | 2.220 |
Why?
|
| Liver Neoplasms | 8 | 2020 | 1381 | 1.660 |
Why?
|
| Neoadjuvant Therapy | 3 | 2022 | 391 | 1.300 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2022 | 1305 | 1.290 |
Why?
|
| Carcinoma, Hepatocellular | 7 | 2020 | 985 | 1.260 |
Why?
|
| Extremities | 2 | 2018 | 83 | 1.110 |
Why?
|
| Fluid Therapy | 2 | 2025 | 147 | 1.070 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2025 | 106 | 1.050 |
Why?
|
| Organometallic Compounds | 4 | 2020 | 111 | 1.010 |
Why?
|
| Pancreatitis, Chronic | 2 | 2025 | 76 | 0.960 |
Why?
|
| Liposarcoma | 2 | 2022 | 23 | 0.950 |
Why?
|
| Pancreatic Neoplasms | 3 | 2025 | 728 | 0.940 |
Why?
|
| Stomach Neoplasms | 2 | 2021 | 565 | 0.910 |
Why?
|
| Postoperative Complications | 5 | 2025 | 3137 | 0.910 |
Why?
|
| Intraoperative Care | 1 | 2025 | 119 | 0.890 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2025 | 168 | 0.890 |
Why?
|
| Lymph Node Excision | 3 | 2022 | 174 | 0.870 |
Why?
|
| Hepatectomy | 3 | 2020 | 119 | 0.860 |
Why?
|
| Gastrectomy | 2 | 2021 | 102 | 0.810 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 2022 | 31 | 0.810 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 1360 | 0.790 |
Why?
|
| Appendiceal Neoplasms | 1 | 2023 | 20 | 0.780 |
Why?
|
| Manganese | 2 | 2019 | 58 | 0.760 |
Why?
|
| Lymph Nodes | 2 | 2021 | 389 | 0.760 |
Why?
|
| Leucovorin | 2 | 2020 | 54 | 0.740 |
Why?
|
| Prognosis | 10 | 2023 | 5010 | 0.740 |
Why?
|
| Contrast Media | 3 | 2021 | 507 | 0.730 |
Why?
|
| Fluorouracil | 2 | 2020 | 138 | 0.720 |
Why?
|
| Colorectal Neoplasms | 2 | 2020 | 632 | 0.720 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2021 | 38 | 0.710 |
Why?
|
| Robotics | 1 | 2022 | 108 | 0.700 |
Why?
|
| Rectal Neoplasms | 1 | 2021 | 81 | 0.670 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2020 | 29 | 0.660 |
Why?
|
| Benchmarking | 1 | 2021 | 138 | 0.660 |
Why?
|
| Manganese Compounds | 1 | 2019 | 9 | 0.640 |
Why?
|
| Picolinic Acids | 1 | 2019 | 11 | 0.640 |
Why?
|
| Diamines | 1 | 2019 | 8 | 0.640 |
Why?
|
| Pancreas | 1 | 2020 | 222 | 0.610 |
Why?
|
| Microvessels | 1 | 2019 | 65 | 0.580 |
Why?
|
| Robotic Surgical Procedures | 1 | 2022 | 222 | 0.580 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2023 | 303 | 0.580 |
Why?
|
| Image Enhancement | 1 | 2019 | 172 | 0.580 |
Why?
|
| Lymphocytes | 1 | 2020 | 363 | 0.580 |
Why?
|
| Surgical Oncology | 1 | 2017 | 13 | 0.560 |
Why?
|
| Neutrophils | 1 | 2020 | 360 | 0.560 |
Why?
|
| Skin Neoplasms | 2 | 2022 | 896 | 0.540 |
Why?
|
| Cecum | 1 | 2017 | 28 | 0.520 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2023 | 3842 | 0.510 |
Why?
|
| Intestinal Volvulus | 1 | 2017 | 40 | 0.500 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2015 | 23 | 0.470 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 396 | 0.450 |
Why?
|
| Middle Aged | 14 | 2025 | 28993 | 0.440 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1340 | 0.440 |
Why?
|
| Retrospective Studies | 11 | 2025 | 17389 | 0.440 |
Why?
|
| Melanoma | 1 | 2022 | 952 | 0.440 |
Why?
|
| Colonoscopy | 1 | 2017 | 252 | 0.440 |
Why?
|
| Abdominal Pain | 1 | 2017 | 314 | 0.430 |
Why?
|
| Colon | 1 | 2017 | 370 | 0.420 |
Why?
|
| ErbB Receptors | 1 | 2015 | 292 | 0.420 |
Why?
|
| Humans | 34 | 2025 | 132064 | 0.410 |
Why?
|
| Decision Making | 1 | 2017 | 700 | 0.380 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 1668 | 0.380 |
Why?
|
| Pancreatectomy | 2 | 2025 | 149 | 0.370 |
Why?
|
| Fibrosis | 4 | 2023 | 421 | 0.360 |
Why?
|
| DNA Methylation | 1 | 2018 | 1123 | 0.350 |
Why?
|
| NF-kappa B | 1 | 2013 | 454 | 0.340 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2022 | 127 | 0.330 |
Why?
|
| Heterocyclic Compounds | 2 | 2020 | 18 | 0.330 |
Why?
|
| Male | 18 | 2025 | 64938 | 0.320 |
Why?
|
| Gadolinium | 2 | 2021 | 116 | 0.310 |
Why?
|
| Liver Neoplasms, Experimental | 2 | 2020 | 59 | 0.310 |
Why?
|
| Aged | 8 | 2025 | 21426 | 0.290 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 1822 | 0.270 |
Why?
|
| Tumor Microenvironment | 2 | 2025 | 686 | 0.260 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 2647 | 0.260 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2022 | 420 | 0.240 |
Why?
|
| Female | 11 | 2025 | 70664 | 0.240 |
Why?
|
| Ileostomy | 1 | 2025 | 32 | 0.230 |
Why?
|
| Animals | 15 | 2023 | 34804 | 0.220 |
Why?
|
| Survival Rate | 2 | 2021 | 2193 | 0.220 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2024 | 4 | 0.210 |
Why?
|
| Quality of Life | 2 | 2025 | 2158 | 0.210 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2024 | 10 | 0.210 |
Why?
|
| Propensity Score | 1 | 2025 | 258 | 0.210 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2024 | 22 | 0.210 |
Why?
|
| Disease Models, Animal | 5 | 2023 | 4684 | 0.200 |
Why?
|
| Nephritis, Hereditary | 1 | 2023 | 20 | 0.200 |
Why?
|
| Lymphatic Metastasis | 2 | 2022 | 442 | 0.200 |
Why?
|
| Cell Line, Tumor | 3 | 2020 | 3682 | 0.200 |
Why?
|
| Signal Transduction | 3 | 2018 | 4710 | 0.200 |
Why?
|
| Pancreaticojejunostomy | 1 | 2022 | 6 | 0.200 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2024 | 79 | 0.200 |
Why?
|
| Mucins | 1 | 2023 | 72 | 0.200 |
Why?
|
| Clinical Decision-Making | 1 | 2025 | 306 | 0.200 |
Why?
|
| Pancreatic Fistula | 1 | 2022 | 30 | 0.200 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2023 | 50 | 0.190 |
Why?
|
| Length of Stay | 2 | 2025 | 1380 | 0.190 |
Why?
|
| Collagen | 2 | 2022 | 303 | 0.190 |
Why?
|
| Sentinel Lymph Node | 1 | 2022 | 11 | 0.190 |
Why?
|
| Mice | 10 | 2023 | 18478 | 0.190 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2022 | 167 | 0.190 |
Why?
|
| Peroxidases | 1 | 2022 | 29 | 0.190 |
Why?
|
| Health Status Disparities | 1 | 2025 | 253 | 0.180 |
Why?
|
| Disease-Free Survival | 2 | 2023 | 956 | 0.180 |
Why?
|
| Coordination Complexes | 1 | 2021 | 7 | 0.180 |
Why?
|
| Lipopolysaccharides | 1 | 2022 | 306 | 0.170 |
Why?
|
| Molecular Probes | 1 | 2020 | 29 | 0.170 |
Why?
|
| Catechin | 1 | 2020 | 13 | 0.160 |
Why?
|
| Hepatic Stellate Cells | 1 | 2020 | 27 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 2 | 2019 | 1049 | 0.160 |
Why?
|
| Platelet Count | 1 | 2020 | 139 | 0.160 |
Why?
|
| Anticarcinogenic Agents | 1 | 2020 | 48 | 0.160 |
Why?
|
| Molecular Imaging | 1 | 2020 | 63 | 0.160 |
Why?
|
| Gadolinium DTPA | 1 | 2019 | 49 | 0.160 |
Why?
|
| Leukocyte Count | 1 | 2020 | 249 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 992 | 0.160 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 5412 | 0.160 |
Why?
|
| Liver Cirrhosis | 4 | 2022 | 898 | 0.150 |
Why?
|
| Tissue Distribution | 1 | 2019 | 380 | 0.150 |
Why?
|
| Quality Improvement | 1 | 2025 | 699 | 0.150 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 1882 | 0.150 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2018 | 19 | 0.150 |
Why?
|
| Transplantation, Heterotopic | 1 | 2018 | 27 | 0.150 |
Why?
|
| Chelating Agents | 1 | 2018 | 46 | 0.150 |
Why?
|
| Autografts | 1 | 2018 | 29 | 0.150 |
Why?
|
| Neoplasms | 1 | 2013 | 2952 | 0.140 |
Why?
|
| Cellular Senescence | 1 | 2020 | 200 | 0.140 |
Why?
|
| Lipogenesis | 1 | 2018 | 60 | 0.140 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 7107 | 0.140 |
Why?
|
| Steroids | 1 | 2019 | 173 | 0.140 |
Why?
|
| Ureteral Obstruction | 1 | 2019 | 105 | 0.140 |
Why?
|
| Adult | 5 | 2025 | 31571 | 0.140 |
Why?
|
| Allografts | 1 | 2018 | 196 | 0.140 |
Why?
|
| Phenotype | 3 | 2020 | 4527 | 0.130 |
Why?
|
| History, 19th Century | 1 | 2017 | 119 | 0.130 |
Why?
|
| Drug Combinations | 1 | 2018 | 280 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 664 | 0.130 |
Why?
|
| Lysophospholipids | 1 | 2016 | 33 | 0.130 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 325 | 0.130 |
Why?
|
| History, 21st Century | 1 | 2017 | 271 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2020 | 1572 | 0.130 |
Why?
|
| Kinetics | 1 | 2018 | 1130 | 0.130 |
Why?
|
| Kidney | 1 | 2023 | 1329 | 0.120 |
Why?
|
| Colectomy | 1 | 2017 | 84 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2017 | 385 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 4 | 2019 | 4757 | 0.120 |
Why?
|
| Genes, erbB-1 | 1 | 2015 | 9 | 0.120 |
Why?
|
| Microsatellite Instability | 1 | 2015 | 40 | 0.120 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2015 | 39 | 0.120 |
Why?
|
| Chromosomal Instability | 1 | 2015 | 60 | 0.120 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2015 | 65 | 0.110 |
Why?
|
| Transcriptome | 2 | 2020 | 1122 | 0.110 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 722 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 482 | 0.110 |
Why?
|
| Kidney Diseases | 1 | 2019 | 489 | 0.110 |
Why?
|
| GTP Phosphohydrolases | 1 | 2015 | 156 | 0.110 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 2311 | 0.110 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 174 | 0.110 |
Why?
|
| CpG Islands | 1 | 2015 | 343 | 0.110 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 342 | 0.100 |
Why?
|
| Liver | 1 | 2021 | 1798 | 0.100 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2015 | 222 | 0.100 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 823 | 0.100 |
Why?
|
| Disease Progression | 2 | 2018 | 2227 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 443 | 0.100 |
Why?
|
| Immunotherapy | 1 | 2018 | 748 | 0.100 |
Why?
|
| Texas | 1 | 2021 | 3627 | 0.100 |
Why?
|
| Rats | 4 | 2020 | 3606 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2015 | 360 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 1017 | 0.090 |
Why?
|
| Prostatitis | 1 | 2011 | 16 | 0.090 |
Why?
|
| Pelvic Pain | 1 | 2011 | 28 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2509 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 2057 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 755 | 0.080 |
Why?
|
| Diethylnitrosamine | 2 | 2020 | 16 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2164 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2015 | 916 | 0.070 |
Why?
|
| G2 Phase | 1 | 2008 | 42 | 0.070 |
Why?
|
| Diet, High-Fat | 2 | 2021 | 255 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 3352 | 0.070 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 1829 | 0.070 |
Why?
|
| Rats, Wistar | 2 | 2018 | 329 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1609 | 0.070 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2008 | 118 | 0.070 |
Why?
|
| Cell Division | 1 | 2008 | 742 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 2008 | 348 | 0.060 |
Why?
|
| Florida | 1 | 2025 | 80 | 0.060 |
Why?
|
| Tissue Array Analysis | 1 | 2025 | 138 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2025 | 547 | 0.050 |
Why?
|
| 2-Aminoadipic Acid | 1 | 2023 | 2 | 0.050 |
Why?
|
| Young Adult | 1 | 2017 | 9952 | 0.050 |
Why?
|
| Hippocampus | 1 | 2008 | 816 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2022 | 72 | 0.050 |
Why?
|
| Patient Readmission | 1 | 2025 | 425 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2022 | 152 | 0.040 |
Why?
|
| Apoptosis | 1 | 2008 | 1899 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2017 | 13000 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2025 | 766 | 0.040 |
Why?
|
| Pyridines | 1 | 2022 | 249 | 0.040 |
Why?
|
| Tea | 1 | 2020 | 18 | 0.040 |
Why?
|
| Piperazines | 1 | 2022 | 255 | 0.040 |
Why?
|
| Gastrointestinal Tract | 1 | 2022 | 232 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2022 | 565 | 0.040 |
Why?
|
| Adolescent | 1 | 2017 | 20542 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 516 | 0.040 |
Why?
|
| Choline | 1 | 2018 | 51 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2018 | 94 | 0.040 |
Why?
|
| Feces | 1 | 2022 | 753 | 0.040 |
Why?
|
| Adiponectin | 1 | 2018 | 128 | 0.040 |
Why?
|
| Neurons | 1 | 2008 | 2002 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2018 | 199 | 0.030 |
Why?
|
| Macrophages | 1 | 2022 | 691 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2018 | 175 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2018 | 588 | 0.030 |
Why?
|
| Precancerous Conditions | 1 | 2020 | 280 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 623 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2019 | 684 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2018 | 1610 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 386 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2025 | 6570 | 0.030 |
Why?
|
| Cell Line | 1 | 2019 | 2725 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 3993 | 0.020 |
Why?
|
| Inflammation | 1 | 2019 | 1519 | 0.020 |
Why?
|
| Mutation | 1 | 2025 | 6226 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 2442 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 3403 | 0.020 |
Why?
|
| Intermediate Filament Proteins | 1 | 2008 | 26 | 0.020 |
Why?
|
| Nestin | 1 | 2008 | 18 | 0.020 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2008 | 36 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2011 | 1234 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2008 | 1045 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 1160 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2008 | 2447 | 0.010 |
Why?
|
| Risk Factors | 1 | 2016 | 10938 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 3043 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2008 | 1133 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2008 | 1964 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2008 | 3865 | 0.010 |
Why?
|